company background image
PRAX logo

Praxis Precision Medicines NasdaqGS:PRAX Stock Report

Last Price

US$59.20

Market Cap

US$783.7m

7D

5.9%

1Y

359.0%

Updated

27 Mar, 2024

Data

Company Financials +

Praxis Precision Medicines, Inc.

NasdaqGS:PRAX Stock Report

Market Cap: US$783.7m

PRAX Stock Overview

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

PRAX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Praxis Precision Medicines, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Praxis Precision Medicines
Historical stock prices
Current Share PriceUS$59.20
52 Week HighUS$67.21
52 Week LowUS$11.85
Beta2.86
1 Month Change24.61%
3 Month Change176.51%
1 Year Change359.02%
3 Year Change-87.95%
5 Year Changen/a
Change since IPO-85.80%

Recent News & Updates

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

Mar 26

Recent updates

Praxis: 2nd Half 2024 ET Readout Could Lead To U.S. Regulatory Filing

Mar 26

Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?

Feb 27
Is There An Opportunity With Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) 26% Undervaluation?

Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Nov 29
Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Aug 14
Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Feb 10
Can Praxis Precision Medicines (NASDAQ:PRAX) Afford To Invest In Growth?

Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Oct 21
Here's Why Praxis Precision Medicines (NASDAQ:PRAX) Must Use Its Cash Wisely

Praxis Precision Medicines GAAP EPS of -$1.32 misses by $0.02

Aug 08

Praxis: MDD Trial Failure May Not Mean An End To Entire Pipeline

Jun 10

We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

May 15
We're Keeping An Eye On Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Jan 27
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Praxis Precision Medicines: Genetic Medicines For Neurological Disease

Nov 23

We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Oct 14
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate

Praxis' PRAX-562 wins Orphan Drug designation for rare encephalopathy

Apr 30

Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Mar 12
Companies Like Praxis Precision Medicines (NASDAQ:PRAX) Are In A Position To Invest In Growth

Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares

Jan 18
Read This Before Selling Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Shares

Praxis Precision's pediatric epilepsy therapies nab Rare Pediatric and Orphan Drug tags in U.S.

Jan 07

Praxis Precision Medicine plummets 27% on clinical hold on lead drug

Nov 10

Shareholder Returns

PRAXUS BiotechsUS Market
7D5.9%0.9%0.4%
1Y359.0%10.3%28.8%

Return vs Industry: PRAX exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: PRAX exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is PRAX's price volatile compared to industry and market?
PRAX volatility
PRAX Average Weekly Movement16.7%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: PRAX's share price has been volatile over the past 3 months.

Volatility Over Time: PRAX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201582Marcio De'Souzahttps://praxismedicines.com

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF.

Praxis Precision Medicines, Inc. Fundamentals Summary

How do Praxis Precision Medicines's earnings and revenue compare to its market cap?
PRAX fundamental statistics
Market capUS$783.71m
Earnings (TTM)-US$123.28m
Revenue (TTM)US$2.45m

320.3x

P/S Ratio

-6.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PRAX income statement (TTM)
RevenueUS$2.45m
Cost of RevenueUS$86.77m
Gross Profit-US$84.32m
Other ExpensesUS$38.96m
Earnings-US$123.28m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-9.31
Gross Margin-3,445.81%
Net Profit Margin-5,037.88%
Debt/Equity Ratio0%

How did PRAX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.